Exicure, Inc. (XCUR): Price and Financial Metrics


Exicure, Inc. (XCUR): $0.13

0.00 (3.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XCUR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XCUR POWR Grades


  • XCUR scores best on the Sentiment dimension, with a Sentiment rank ahead of 58.6% of US stocks.
  • The strongest trend for XCUR is in Sentiment, which has been heading up over the past 35 days.
  • XCUR ranks lowest in Momentum; there it ranks in the 18th percentile.

XCUR Stock Summary

  • Exicure Inc's market capitalization of $26,154,883 is ahead of only 4.75% of US-listed equities.
  • As for revenue growth, note that XCUR's revenue has grown -102.91% over the past 12 months; that beats the revenue growth of only 0.54% of US companies in our set.
  • In terms of volatility of its share price, XCUR is more volatile than 99.2% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Exicure Inc, a group of peers worth examining would be CBIO, CDTX, IVA, AFMD, and ZYME.
  • XCUR's SEC filings can be seen here. And to visit Exicure Inc's official web site, go to www.exicuretx.com.

XCUR Valuation Summary

  • In comparison to the median Healthcare stock, XCUR's price/sales ratio is 196.92% higher, now standing at 33.7.
  • XCUR's price/sales ratio has moved up 21.1 over the prior 40 months.
  • Over the past 40 months, XCUR's EV/EBIT ratio has gone up 7.2.

Below are key valuation metrics over time for XCUR.

Stock Date P/S P/B P/E EV/EBIT
XCUR 2021-08-31 33.7 3.4 -2.6 -2.2
XCUR 2021-08-30 32.3 3.2 -2.4 -2.1
XCUR 2021-08-27 33.0 3.3 -2.5 -2.2
XCUR 2021-08-26 32.3 3.2 -2.4 -2.1
XCUR 2021-08-25 32.0 3.2 -2.4 -2.1
XCUR 2021-08-24 30.6 3.1 -2.3 -2.0

XCUR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XCUR has a Quality Grade of C, ranking ahead of 38.19% of graded US stocks.
  • XCUR's asset turnover comes in at 0.039 -- ranking 338th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows XCUR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.039 1 -0.674
2021-03-31 0.085 1 -0.500
2020-12-31 0.161 1 -0.327
2020-09-30 0.157 1 -0.336
2020-06-30 0.152 1 -0.444
2020-03-31 0.133 1 -0.757

XCUR Price Target

For more insight on analysts targets of XCUR, see our XCUR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.38 (Strong Buy)

XCUR Stock Price Chart Interactive Chart >

Price chart for XCUR

XCUR Price/Volume Stats

Current price $0.13 52-week high $1.98
Prev. close $0.12 52-week low $0.10
Day low $0.12 Volume 9,750,700
Day high $0.13 Avg. volume 12,958,305
50-day MA $0.17 Dividend yield N/A
200-day MA $0.56 Market Cap 15.42M

Exicure, Inc. (XCUR) Company Bio


Exicure, Inc. operates as a clinical stage bio-technology company. The Company develops a new class of immunomodulatory and gene regulating drugs against validated targets, as well as addresses diseases such as oncology, immunology, and dermatology. Exicure serves customers in the United States.


XCUR Latest News Stream


Event/Time News Detail
Loading, please wait...

XCUR Latest Social Stream


Loading social stream, please wait...

View Full XCUR Social Stream

Latest XCUR News From Around the Web

Below are the latest news stories about Exicure Inc that investors may wish to consider to help them evaluate XCUR as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Rise and shine, trader!

William White on InvestorPlace | March 2, 2022

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

Final Deadline Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

Final Deadline Alert: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

NewMediaWire | February 11, 2022

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

NewMediaWire | February 10, 2022

Deadline Friday Notice: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

Deadline Friday Notice: The Schall Law Firm Encourages Investors In Exicure, Inc. With Losses Of $100,000 To Contact The Firm

NewMediaWire | February 9, 2022

Read More 'XCUR' Stories Here

XCUR Price Returns

1-mo -7.14%
3-mo -35.10%
6-mo -72.28%
1-year -92.22%
3-year -95.49%
5-year N/A
YTD -35.68%
2021 -88.58%
2020 -38.11%
2019 -19.21%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3807 seconds.